Deals: Page 10
-
Justin Sullivan via Getty Images
Bausch + Lomb bulks up OTC business with J&J deal
The eye care company has become an active acquirer under new CEO Brent Saunders, buying an eye drop product line one week after purchasing several medicines from Novartis.
By Ned Pagliarulo • July 6, 2023 -
Courtesy of Thermo Fisher Scientific
Thermo Fisher to buy real-world evidence company CorEvitas for $913M
The contract services provider, which secured the deal through a reportedly competitive process, expects CorEvitas to expand its drug research business.
By Elise Reuter • July 6, 2023 -
Courtesy of Sarepta
Sarepta sells FDA fast pass earned from Duchenne gene therapy approval
The deal enables Sarepta to quickly cash in on the clearance of Elevidys, with $102 million in new funds to help bankroll its drug research.
By Jonathan Gardner • July 5, 2023 -
Permission granted by Novartis
Novartis, continuing revamp, sells eye drugs to Bausch + Lomb for up to $2.5B
An agreement to divest the dry eye disease treatment Xiidra and a few other medicines adds to the Swiss pharma's yearslong push to slim down from the healthcare conglomerate it once was.
By Jonathan Gardner • June 30, 2023 -
Courtesy of Eli Lilly
Lilly to acquire cancer antibody drug startup Emergence
The yet-to-be-announced deal for the German biotech is the latest move by Lilly to bulk up its oncology business, adding a drug in early development for solid tumors.
By Gwendolyn Wu , Ben Fidler • June 29, 2023 -
Kris Tripplaar/Sipa/Newscom
Lilly takes over partner working on cell therapies for diabetes
Sigilon Therapeutics, a biotech that’s been collaborating with Lilly since 2018, has agreed to be bought for up to $310 million in the pharma’s second announced buyout this month.
By Jacob Bell • June 29, 2023 -
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
FTC proposes updates to merger review that could slow healthcare dealmaking
A new rule proposed by antitrust regulators would ask companies to provide additional information about planned mergers to help the Federal Trade Commission keep pace with increased deal volume and complexity.
By Emily Olsen • June 28, 2023 -
maciek905 via Getty Images
Talaris, Tourmaline to combine in biotech’s latest reverse merger
The deal is the latest in a recent string of reverse mergers, which are enabling startups to sidestep initial public offerings in a difficult funding climate.
By Kristin Jensen • June 22, 2023 -
Courtesy of Eli Lilly
Lilly to buy oral immune drug developer Dice Therapeutics for $2.4B
The deal signals pharma’s continued interest in pills for inflammatory conditions, which are meant to approach the potency of injectable therapies.
By Ben Fidler • June 20, 2023 -
Spencer Platt via Getty Images
Coherus doubles down on immuno-oncology with latest deal
Known for its work in biosimilars, Coherus will acquire two drugs in testing for cancer through a roughly $65 million buyout of Surface Oncology.
By Jacob Bell • June 16, 2023 -
RiverNorthPhotography via Getty Images
Pfizer refiles Seagen deal paperwork with regulators
Andrew Berens, an analyst at SVB Securities, noted Wednesday’s refiling could be a strategy to provide the FTC with more information, but sidestep a more onerous “second request.”
By Ned Pagliarulo • Updated June 14, 2023 -
Permission granted by Novartis
Novartis to acquire kidney disease biotech Chinook for up to $3.5B
The Swiss pharma is betting that two experimental drugs the biotech has developed for IgA nephropathy will succeed in late-stage testing, one of which will deliver results later this year.
By Ben Fidler • June 12, 2023 -
Md Saiful Islam Khan via Getty Images
Antibiotic maker Paratek, low on cash, agrees to a buyout
Gurnet Point Capital and Novo Holdings aim to take Paratek private in a deal that highlights the challenges small biotechs face selling new antibiotics.
By Ben Fidler • June 6, 2023 -
Joe Raedle via Getty Images
Novo Nordisk in talks to acquire French device-maker Biocorp for $165M
Biocorp’s “smart pen” technology could improve diabetes management and potentially be used in other areas Novo works in like obesity, one analyst said.
By Elise Reuter • Updated June 6, 2023 -
monsitj via Getty Images
Concentra bids on Atea, seeking to acquire another struggling biotech
However, Atea’s board said Tuesday they rejected the offer from Concentra, which was recently involved in the takeover of Jounce Therapeutics.
By Gwendolyn Wu • Updated May 30, 2023 -
Elizabeth Regan/BioPharma Dive
Ironwood to buy rare disease drugmaker in billion-dollar deal
The acquisition would give Ironwood a drug in late-stage testing for a condition known as short bowel syndrome, further building out the company’s gastrointestinal-focused research.
By Jacob Bell • May 22, 2023 -
Carol Highsmith. (2005). "The Apex Building" [Photo]. Retrieved from Wikimedia Commons.
On heels of Amgen lawsuit, FTC broadens investigation of PBMs
The regulator is probing the business practices of two more drug purchasing organizations, deepening an investigation that began last year.
By Kristin Jensen • May 18, 2023 -
Meletios Verras via Getty Images
Biotech Scribe strikes gene editing deal with Lilly subsidiary
The California-based company now has partnerships in place with Sanofi, Biogen and Lilly’s Prevail.
By Gwendolyn Wu • May 16, 2023 -
Brian Tucker/BioPharma Dive
FTC sues to block Amgen’s $27.8B deal for Horizon
The regulator’s challenge will test a more expansive view of how pharmaceutical mergers could harm consumers. Amgen remains confident it can complete the deal, however.
By Jonathan Gardner • May 16, 2023 -
Permission granted by Gilead Sciences
Gilead expands Arcus partnership, with eye to inflammatory disease
The new deal is worth up to $1 billion, and will see the two collaborators work together on up to four inflammatory disease drug targets.
By Jonathan Gardner • May 15, 2023 -
Dr_Microbe via Getty Images
A struggling biotech wraps its main assets into a new drug company
Cyclerion Therapeutics has struck an agreement to sell two of its experimental drugs, known as sGC stimulators, to a newly formed company in exchange for cash and equity.
By Jacob Bell • May 12, 2023 -
Elizabeth Regan/BioPharma Dive
Pharma contractor Syneos to be taken private in $7.1B deal
The offer from a group of private equity firms comes after a series of ups and downs for Syneos, which was formed through the 2017 merger of contract research firms InVentiv Health and INC Research.
By Kristin Jensen • May 10, 2023 -
OGphoto via Getty Images
FibroGen grabs an option to buy cancer drug startup Fortis
The deal, which gives FibroGen four years to acquire Fortis at a pre-negotiated price, allows the startup to earn returns for its investors without relying on an IPO in a tough market.
By Gwendolyn Wu • May 9, 2023 -
Permission granted by Gilead Sciences
Gilead acquires San Diego startup for early-stage cancer, immune drugs
The buyout of privately held XinThera continues a string of recent acquisitions of smaller biotechs by Gilead and hands it a group of drug prospects that could begin clinical testing later this year.
By Ned Pagliarulo • May 9, 2023 -
iStock via Getty Images
Roche pays China-based biotech $70M for a new HER2 drug
The drug, currently in Phase 1, is an oral medicine designed to cross the blood-brain barrier and better treat HER2 tumors that have spread to the brain.
By Jonathan Gardner • May 9, 2023
Previous
